Drug & intervention

estramustine

RxCUI 4089

Clinical trials18
Recruiting0
Related conditions8
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Estramustine

Estramustine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, BANTooltip British Approved Name) is an estrogen and cytostatic antineoplastic agent which was never marketed. It is a carbamate derivative of estradiol and acts in part as a prodrug of estradiol in the body. Estramustine phosphate, the C17β phosphate ester of estramustine and a prodrug of estramustine, estromustine, estradiol, and estrone, is marketed and used in the treatment of prostate cancer.

Read on Wikipedia ↗ Wikidata Q412939 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

18 shown
Efficacy and Safety of Estracyt® in Metastatic Breast CancerNCT02853071 · 2017-01-01
WITHDRAWN
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate CancerNCT02560051 · 2015-11-01
TERMINATED
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate CancerNCT02494713 · 2015-10-01
TERMINATED
Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.NCT02866955 · 2011-06-15
COMPLETED
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate CancerNCT00193271 · 2004-08-01
COMPLETED
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local TreatmentNCT00165399 · 2004-03-01
COMPLETED
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic CancerNCT00541281 · 2003-12-01
COMPLETED
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the ProstateNCT00151073 · 2002-04-01
COMPLETED
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate CancerNCT00151086 · 2001-12-01
COMPLETED
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate CancerNCT00028769 · 2001-12-01
COMPLETED
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate CancerNCT00016913 · 2001-05-01
COMPLETED
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.NCT00183924 · 2001-03-01
COMPLETED
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate CancerNCT01250717 · 2001-01-01
COMPLETED
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate CarcinomaNCT00038246 · 2000-10-01
COMPLETED
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate CarcinomaNCT00193193 · 2000-08-01
COMPLETED
Intravenous Estramustine With Taxol in Hormone Refractory Prostate AdenocarcinomaNCT00038168 · 2000-06-01
COMPLETED
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone TherapyNCT00004001 · 1999-10-01
COMPLETED
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the ProstateNCT00151060 · 1998-12-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.